Tudor Investment Corp
AMLX icon

Tudor Investment Corp’s Amylyx Pharmaceuticals AMLX Stock Holding History

Tudor Investment Corp’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$436K Buy
31,334
+8,932
+40% +$126K ﹤0.01% 2903
2025
Q4 		$271K Buy
+22,402
New +$304K ﹤0.01% 3116
2025
Q3 		– Sell
-12,073
Closed -$77.4K – 3321
2025
Q2 		$77.4K Sell
12,073
-21,355
-64% -$104K ﹤0.01% 3160
2025
Q1 		$118K Sell
33,428
-259
-0.8% -$922 ﹤0.01% 2929
2024
Q4 		$127K Buy
+33,687
New +$159K ﹤0.01% 2896
2024
Q2 		– Sell
-12,753
Closed -$36.2K – 2288
2024
Q1 		$36.2K Sell
12,753
-20,899
-62% -$273K ﹤0.01% 2124
2023
Q4 		$495K Buy
33,652
+6,293
+23% +$96.5K ﹤0.01% 1801
2023
Q3 		$501K Sell
27,359
-32,256
-54% -$682K 0.01% 1680
2023
Q2 		$1.29M Buy
59,615
+22,051
+59% +$596K 0.02% 1162
2023
Q1 		$1.1M Buy
37,564
+1,567
+4% +$54.4K 0.02% 1137
2022
Q4 		$1.33M Buy
35,997
+19,859
+123% +$705K 0.03% 895
2022
Q3 		$454K Buy
+16,138
New +$403K 0.01% 1468

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Tudor Investment Corp's AMLX Position: Q1 2026 in Review

Tudor Investment Corp increased its Amylyx Pharmaceuticals (AMLX) stake by 40% in Q1 2026, buying an estimated $126K and bringing the position to 31,334 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #2903.

Tudor Investment Corp first reported a position in AMLX in Q3 2022 and has held it in 12 quarters since. The position peaked at $1.33M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Tudor Investment Corp held 31,334 shares of Amylyx Pharmaceuticals worth $436K as of Q1 2026.
  • Tudor Investment Corp bought 8,932 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $126K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #2903 holding.
  • Tudor Investment Corp first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
  • Tudor Investment Corp's Amylyx Pharmaceuticals position peaked at $1.33M in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.